These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 33704801)

  • 21. Head-to-head comparison of prasugrel versus ticagrelor in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
    Sakurai R; Burazor I; Bonneau HN; Kaneda H
    J Interv Cardiol; 2017 Oct; 30(5):457-464. PubMed ID: 28804959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Aradi D; Komócsi A; Vorobcsuk A; Serebruany VL
    Thromb Haemost; 2013 Jan; 109(1):93-101. PubMed ID: 23197191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prasugrel vs. Ticagrelor for Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.
    Khan MS; Memon MM; Usman MS; Alnaimat S; Khan SU; Khan AR; Yamani N; Fugar S; Mookadam F; Krasuski RA; Doukky R
    Am J Cardiovasc Drugs; 2019 Oct; 19(5):465-476. PubMed ID: 30828769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of oral P2Y12 inhibitors on residual thrombus burden and reperfusion indexes in patients with ST-segment elevation myocardial infarction.
    Di Vito L; Versaci F; Limbruno U; Pawlowski T; Gatto L; Romagnoli E; Cattabiani MA; Micari A; Trivisonno A; Marco V; Prati F
    J Cardiovasc Med (Hagerstown); 2016 Sep; 17(9):701-6. PubMed ID: 27467458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meta-Analysis Comparing P2Y
    Baldetti L; Melillo F; Moroni F; Gallone G; Pagnesi M; Venuti A; Beneduce A; Calvo F; Gramegna M; Godino C; D'Ascenzo F; De Ferrari GM; Capodanno D; Cappelletti AM
    Am J Cardiol; 2020 Jun; 125(12):1815-1822. PubMed ID: 32305225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M
    Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intensified P2Y12 inhibition for high-on treatment platelet reactivity.
    Mshelbwala FS; Hugenberg DW; Kreutz RP
    J Thromb Thrombolysis; 2020 Oct; 50(3):619-627. PubMed ID: 32152791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trends for and Clinical Factors Associated with Choice of Oral P2Y
    Jain N; Hunt SL; Cui H; Phadnis MA; Mahnken JD; Shireman TI; Dai J; Mehta JL; Rasu RS
    Cardiovasc Drugs Ther; 2019 Oct; 33(5):511-521. PubMed ID: 31729588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of a Real-World In-Hospital Antiplatelet-Switching Strategy Following Coronary Interventions: The SWITCH Study.
    Soueid AE; Kassas I; Rade J; Kakouros N
    J Invasive Cardiol; 2021 Apr; 33(4):E263-E268. PubMed ID: 33794478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Ticagrelor in Diabetes Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials.
    Zhang Z; Chen O
    J Cardiovasc Pharmacol; 2021 May; 77(5):536-543. PubMed ID: 33760801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative.
    Faridi KF; Garratt KN; Kennedy KF; Maddox TM; Secemsky EA; Butala NM; Yeh RW
    Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e006275. PubMed ID: 32156164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triple Antithrombotic Therapy With Aspirin, P2Y12 Inhibitor, and Warfarin After Percutaneous Coronary Intervention: An Evaluation of Prasugrel or Ticagrelor Versus Clopidogrel.
    Verlinden NJ; Coons JC; Iasella CJ; Kane-Gill SL
    J Cardiovasc Pharmacol Ther; 2017 Nov; 22(6):546-551. PubMed ID: 28279076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis.
    Wen M; Li Y; Qu X; Zhu Y; Tian L; Shen Z; Yang X; Shi X
    BMC Cardiovasc Disord; 2020 Oct; 20(1):430. PubMed ID: 33004000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Genotype-Guided Strategy for Oral P2Y
    Claassens DMF; Vos GJA; Bergmeijer TO; Hermanides RS; van 't Hof AWJ; van der Harst P; Barbato E; Morisco C; Tjon Joe Gin RM; Asselbergs FW; Mosterd A; Herrman JR; Dewilde WJM; Janssen PWA; Kelder JC; Postma MJ; de Boer A; Boersma C; Deneer VHM; Ten Berg JM
    N Engl J Med; 2019 Oct; 381(17):1621-1631. PubMed ID: 31479209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Malik AH; Gupta R; Chakraborty S; Mahajan P; Bandyopadhyay D; Yandrapalli S; Zaid S; Sreenivasan J; Chaturvedi A; Mehta SS; Vyas AV; Patel NC; Combs WG; Ahmad H
    Cardiovasc Revasc Med; 2022 Aug; 41():115-121. PubMed ID: 35033458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching to Clopidogrel in Patients With Acute Coronary Syndrome Managed With Percutaneous Coronary Intervention Initially Treated With Prasugrel or Ticagrelor: Systematic Review and Meta-analysis.
    Hong J; Turgeon RD; Pearson GJ
    Ann Pharmacother; 2019 Oct; 53(10):997-1004. PubMed ID: 30999764
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute coronary syndrome undergoing coronary artery stenting: a randomized, blinded, parallel study.
    Schnorbus B; Daiber A; Jurk K; Warnke S; Koenig J; Lackner KJ; Münzel T; Gori T
    Eur Heart J; 2020 Sep; 41(33):3144-3152. PubMed ID: 31899473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies.
    Jia M; Li Z; Chu H; Li L; Chen K
    Med Sci Monit; 2015 Apr; 21():1131-7. PubMed ID: 25893318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016.
    Dayoub EJ; Seigerman M; Tuteja S; Kobayashi T; Kolansky DM; Giri J; Groeneveld PW
    JAMA Intern Med; 2018 Jul; 178(7):943-950. PubMed ID: 29799992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized Comparison of Oral P2Y
    Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
    JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.